This study plans to enroll 60 patients with CEA-positive metastatic or unresectable solid tumors, such as gastric cancer, colon cancer, rectal cancer, esophageal cancer, and pancreatic cancer, who have progressed after at least two lines of chemotherapy. Here, CEACAM5 is linked to esophageal cancer.